BidaskClub Upgrades Heron Therapeutics (NASDAQ:HRTX) to Hold

Heron Therapeutics (NASDAQ:HRTX) was upgraded by research analysts at BidaskClub from a “sell” rating to a “hold” rating in a research note issued to investors on Saturday, BidAskClub reports.

A number of other equities research analysts have also weighed in on the stock. Guggenheim started coverage on shares of Heron Therapeutics in a report on Tuesday, May 26th. They issued a “buy” rating and a $24.00 target price on the stock. Northland Securities began coverage on shares of Heron Therapeutics in a research report on Thursday, August 6th. They set a “buy” rating and a $35.00 target price for the company. SVB Leerink reduced their target price on shares of Heron Therapeutics from $26.00 to $19.00 and set an “outperform” rating for the company in a research report on Tuesday, June 30th. Finally, Stifel Nicolaus reissued a “buy” rating on shares of Heron Therapeutics in a research report on Tuesday, September 8th. Three analysts have rated the stock with a hold rating and nine have assigned a buy rating to the company’s stock. Heron Therapeutics currently has a consensus rating of “Buy” and a consensus target price of $30.44.

Heron Therapeutics stock opened at $16.28 on Friday. The business has a 50 day moving average price of $15.13 and a two-hundred day moving average price of $15.69. Heron Therapeutics has a 12 month low of $9.60 and a 12 month high of $26.81.

Heron Therapeutics (NASDAQ:HRTX) last released its quarterly earnings data on Wednesday, August 5th. The biotechnology company reported ($0.61) earnings per share for the quarter, beating the consensus estimate of ($0.64) by $0.03. Heron Therapeutics had a negative return on equity of 57.52% and a negative net margin of 157.65%. The company had revenue of $22.67 million for the quarter, compared to analyst estimates of $16.35 million. As a group, analysts expect that Heron Therapeutics will post -2.47 earnings per share for the current fiscal year.

Several institutional investors and hedge funds have recently bought and sold shares of HRTX. First Trust Advisors LP boosted its holdings in shares of Heron Therapeutics by 6.1% in the first quarter. First Trust Advisors LP now owns 75,331 shares of the biotechnology company’s stock valued at $1,841,000 after acquiring an additional 4,335 shares during the period. UBS Group AG grew its position in Heron Therapeutics by 27.2% during the 1st quarter. UBS Group AG now owns 125,320 shares of the biotechnology company’s stock worth $1,471,000 after acquiring an additional 26,784 shares during the last quarter. Arizona State Retirement System bought a new stake in Heron Therapeutics during the 1st quarter worth approximately $236,000. New York State Common Retirement Fund grew its position in Heron Therapeutics by 4.5% during the 1st quarter. New York State Common Retirement Fund now owns 184,328 shares of the biotechnology company’s stock worth $2,164,000 after acquiring an additional 7,894 shares during the last quarter. Finally, Rhumbline Advisers grew its position in Heron Therapeutics by 4.0% during the 1st quarter. Rhumbline Advisers now owns 117,716 shares of the biotechnology company’s stock worth $1,382,000 after acquiring an additional 4,489 shares during the last quarter. Institutional investors and hedge funds own 96.49% of the company’s stock.

Heron Therapeutics Company Profile

Heron Therapeutics, Inc, a biotechnology company, engages in developing treatments to address unmet medical needs. The company's product candidates utilize its proprietary Biochronomer drug delivery technology, which delivers therapeutic levels of a range of short-acting pharmacological agents over a period from days to weeks with a single administration.

See Also: How Do You Calculate Return on Investment (ROI)?

Analyst Recommendations for Heron Therapeutics (NASDAQ:HRTX)

Receive News & Ratings for Heron Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Heron Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.